Patricia Kropf on Home Administration of Synribo for CML

Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).

In May 2014, the FDA approved home administration of the subcutaneous injection for patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to treatment with tyrosine-kinase inhibitors (TKIs).

Prior to the approval, patients had to travel to the clinic to receive their injections, which Kropf says was burdensome and inconvenient. The injections can be administered by the patients or caregivers.

Kropf adds that she anticipates seeing an expansion of Synribo prescriptions because of the approval.